AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19803620 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention to improve medication adherence and reduce relapse
Number of subjects: 144
Study 19803620 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 144
Study 17103307 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g L-Arg
Number of subjects: 8
Study 17103307 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g L-Arg
Number of subjects: 8
Study 17103307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 14523338 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% GTN ointment
Number of subjects: 15
Study 14523338 — intervention group
Group type: COMPARATOR
Intervention: 0.1% GTN ointment
Number of subjects: 15
Study 10636519 — intervention group
Group type: EXPERIMENTAL
Intervention: One double-bite suture on each side of the urethra (Group A)
Number of subjects: 161
Study 10636519 — intervention group
Group type: EXPERIMENTAL
Intervention: Two single-bite sutures on each side of the urethra (Group B)
Number of subjects: 161
Study 8708839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocath (22-gauge hydrophilic coated polyurethane catheter)
Number of subjects: 58
Study 8708839 — intervention group
Group type: COMPARATOR
Intervention: Silastic catheter (23-gauge silastic catheter)
Number of subjects: 58
Study 1559321 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide (D.RET.) 250 mg twice daily
Number of subjects: 76
Study 1559321 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone 1200 mg daily for 10 days, then 200 mg daily
Number of subjects: 76
Study 4014620 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg controlled-release oral morphine
Number of subjects: 30
Study 4014620 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg controlled-release oral morphine
Number of subjects: 30
Study 4014620 — intervention group
Group type: COMPARATOR
Intervention: 15 mg intramuscular morphine
Number of subjects: 30
Study 31285591 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus bevacizumab (BEV)
Number of subjects: 122
Study 31285591 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFOX6 plus cetuximab (CET)
Number of subjects: 122
Study 29739782 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self‐management intervention for blood pressure self‐monitoring and medication change
Number of subjects: 35
Study 29739782 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital self‐management intervention
Number of subjects: 35
Study 26265465 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week exercise programme (aerobic and strength training)
Number of subjects: 855
Study 26265465 — intervention group
Group type: COMPARATOR
Intervention: Regular antenatal care (Control)
Number of subjects: 855
Study 24894436 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated pain management program supplemented with peer volunteers
Number of subjects: 30
Study 24894436 — intervention group
Group type: COMPARATOR
Intervention: Control group not explicitly mentioned
Number of subjects: 30
Study 22477640 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated inpatient rehabilitation programme with aftercare
Number of subjects: 411
Study 22477640 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation programme without aftercare
Number of subjects: 411
Study 20200423 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial telephone counseling (PTC)
Number of subjects: 90
Study 20200423 — intervention group
Group type: COMPARATOR
Intervention: Standard genetic counseling (SGC)
Number of subjects: 90
Study 17470398 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless (implicit) learning method
Number of subjects: 0
Study 17470398 — intervention group
Group type: COMPARATOR
Intervention: Errorful (explicit) learning method
Number of subjects: 0
Study 15843729 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib (Celebrex)
Number of subjects: 0
Study 15843729 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (Indocid)
Number of subjects: 0
Study 15843729 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 12032741 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbal treatment (90 mg ephedrine alkaloids and 192 mg caffeine per day)
Number of subjects: 167
Study 12032741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 11078251 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm regularization following direct-current cardioversion
Number of subjects: 10
Study 11078251 — intervention group
Group type: COMPARATOR
Intervention: Atrial fibrillation (irregular rhythm)
Number of subjects: 10
Study 8641638 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0
Study 8641638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1467659 — intervention group
Group type: EXPERIMENTAL
Intervention: Local intravaginal application of metronidazole (500 mg)
Number of subjects: 114
Study 1467659 — intervention group
Group type: COMPARATOR
Intervention: Single-shot prophylaxis with cefuroxime (1,500 mg intravenously)
Number of subjects: 114
Study 6507770 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with initial peridural injection of 100 μg fentanyl
Number of subjects: 203
Study 6507770 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine
Number of subjects: 203
Study 31659559 — intervention group
Group type: EXPERIMENTAL
Intervention: Traction device‐assisted ESD (group B)
Number of subjects: 41
Study 31659559 — intervention group
Group type: COMPARATOR
Intervention: Conventional ESD (group A)
Number of subjects: 41
Study 30122200 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product containing hydrolyzed fish collagen, vitamins, antioxidants, and other active ingredients, taken daily for 90 days.
Number of subjects: 120
Study 30122200 — intervention group
Group type: EXPERIMENTAL
Intervention: Test product
Number of subjects: 120
Study 27858912 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC + MVC (n=10)
Number of subjects: 20
Study 27858912 — intervention group
Group type: COMPARATOR
Intervention: SOC (n=9)
Number of subjects: 20
Study 27858912 — intervention group
Group type: EXPERIMENTAL
Intervention: MVC intensification
Number of subjects: 20
Study 25189855 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine
Number of subjects: 44
Study 25189855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 22473652 — intervention group
Group type: EXPERIMENTAL
Intervention: careHPV test
Number of subjects: 387
Study 19835832 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 290
Study 19835832 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine plus Primaquine (CQ+PQ)
Number of subjects: 290
Study 17324823 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal medium-depth chemical peel (70% glycolic acid and 35% TCA)
Number of subjects: 25
Study 17324823 — intervention group
Group type: COMPARATOR
Intervention: Cryosurgery
Number of subjects: 25
Study 16400485 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir and Prednisone (A+P group)
Number of subjects: 46
Study 16400485 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (P group)
Number of subjects: 46
Study 11236211 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination topical gel (5% benzoyl peroxide and 1% clindamycin)
Number of subjects: 159
Study 11236211 — intervention group
Group type: COMPARATOR
Intervention: 1% clindamycin gel
Number of subjects: 159
Study 9428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg daily
Number of subjects: 451
Study 9428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg daily
Number of subjects: 451
Study 9428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1500 mg daily
Number of subjects: 451
Study 9428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2000 mg daily
Number of subjects: 451
Study 9428832 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 2500 mg daily
Number of subjects: 451
Study 9428832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 451
Study 8484150 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program during working hours to improve back muscle strength, endurance, and coordination
Number of subjects: 0
Study 8484150 — intervention group
Group type: COMPARATOR
Intervention: No exercise program (Control)
Number of subjects: 0
Study 8484150 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapist intervention for training group
Number of subjects: 0
Study 3303439 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine and low-dose prednisolone (AP)
Number of subjects: 78
Study 3303439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (Cy)
Number of subjects: 78
Study 3303439 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-AB matching
Number of subjects: 78
Study 3303439 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-DR matching
Number of subjects: 78
Study 2526721 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA), 150 mg/day
Number of subjects: 10
Study 2526721 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 4602899 — intervention group
Group type: EXPERIMENTAL
Intervention: To‐336 vaccine
Number of subjects: 142
Study 4602899 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV77. DE‐5 vaccine
Number of subjects: 142
Study 4602899 — intervention group
Group type: EXPERIMENTAL
Intervention: RA27/3 vaccine
Number of subjects: 142
Study 4602899 — intervention group
Group type: EXPERIMENTAL
Intervention: Cendehill vaccine
Number of subjects: 142
Study 31400515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 12 weeks
Number of subjects: 0
Study 31400515 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil for 12 weeks
Number of subjects: 0
Study 31400515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of CBT and modafinil for 12 weeks
Number of subjects: 0
Study 31400515 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 31400515 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil
Number of subjects: 0
Study 31400515 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of CBT and modafinil
Number of subjects: 0
Study 28203020 — intervention group
Group type: EXPERIMENTAL
Intervention: CFNB combined with PLIA (20 mL ropivacaine 5 g/L)
Number of subjects: 100
Study 28203020 — intervention group
Group type: COMPARATOR
Intervention: CFNB alone (normal saline)
Number of subjects: 100
Study 26542509 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-month supervised lifestyle intervention (exercise training, reduced sodium and calorie DASH eating plan, weight management)
Number of subjects: 150
Study 26542509 — intervention group
Group type: COMPARATOR
Intervention: Standardized education and physician advice
Number of subjects: 150
Study 22869047 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based instructional strategies
Number of subjects: 995
Study 21621331 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test (TSST)
Number of subjects: 45
Study 19489935 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone augmented with rhBMP-2 (test)
Number of subjects: 11
Study 19489935 — intervention group
Group type: COMPARATOR
Intervention: Bone augmented without rhBMP-2 (control)
Number of subjects: 11
Study 16763334 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐a2a (9 MU three times a week) and lamivudine (100 mg daily) for 12 months (Group 1)
Number of subjects: 68
Study 16763334 — intervention group
Group type: COMPARATOR
Intervention: IFN‐a2a alone (9 MU three times a week) for 12 months (Group 2)
Number of subjects: 68
Study 16763334 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐a2a and lamivudine (Group 1)
Number of subjects: 68
Study 16763334 — intervention group
Group type: COMPARATOR
Intervention: IFN‐a2a alone (Group 2)
Number of subjects: 68
Study 15622423 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual ambulatory assistance
Number of subjects: 38
Study 15622423 — intervention group
Group type: COMPARATOR
Intervention: Group educational program
Number of subjects: 38
Study 11145797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 985
Study 11145797 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus ointment 0.1%
Number of subjects: 985
Study 11145797 — intervention group
Group type: COMPARATOR
Intervention: Vehicle ointment
Number of subjects: 985
Study 9024746 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.625 mg/day of Premarin)
Number of subjects: 10
Study 9024746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 8299660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 10 mg
Number of subjects: 40
Study 8299660 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol 20 mg
Number of subjects: 40
Study 8299660 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline 5 mg
Number of subjects: 40
Study 8299660 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 7.5 mg
Number of subjects: 40
Study 8299660 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 10 mg vs Terbutaline 7.5 mg
Number of subjects: 40
Study 8299660 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 10 mg vs Bambuterol 20 mg
Number of subjects: 40
Study 8299660 — intervention group
Group type: COMPARATOR
Intervention: Bambuterol 20 mg vs Terbutaline high dose
Number of subjects: 40
Study 3571318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of ligamentous injuries
Number of subjects: 30
Study 3571318 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment of ligamentous injuries
Number of subjects: 30
Study 29084067 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching plus metronome
Number of subjects: 70
Study 29084067 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching plus visual feedback
Number of subjects: 70
Study 29084067 — intervention group
Group type: COMPARATOR
Intervention: Coaching alone (control)
Number of subjects: 70
Study 29084067 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analysis of male versus female
Number of subjects: 70
Study 29784592 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) based care in an acute elderly care unit
Number of subjects: 408
Study 29784592 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (control group)
Number of subjects: 408
Study 26433763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) in routine care
Number of subjects: 574
Study 26433763 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT) in RCTs
Number of subjects: 574
Study 25551813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sciatic-femoral nerve block with levobupivacaine 0.5% (40 ml)
Number of subjects: 40
Study 25551813 — intervention group
Group type: COMPARATOR
Intervention: Spinal anaesthesia with 7.5 mg levobupivacaine 0.5%
Number of subjects: 40
Study 22286203 — intervention group
Group type: EXPERIMENTAL
Intervention: aripiprazole 2 mg/day
Number of subjects: 225
Study 22286203 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 225
Study 20441798 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine replacement
Number of subjects: 17
Study 19126178 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led telemonitoring intervention
Number of subjects: 109
Study 19126178 — intervention group
Group type: COMPARATOR
Intervention: Regular outpatient care (Control)
Number of subjects: 109
Study 16330624 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic detection and multidisciplinary treatment of depression (consultation and treatment by a psychiatrist, follow-up by a research nurse and family physician)
Number of subjects: 157
Study 16330624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study 12698500 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg bid of theophylline (Unilong)
Number of subjects: 37
Study 12698500 — intervention group
Group type: EXPERIMENTAL
Intervention: 375 mg bid of theophylline (Unilong)
Number of subjects: 37
Study 12698500 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 37
Study 10648261 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L unfiltered cafetière (French press) coffee daily for 2 weeks
Number of subjects: 64
Study 10648261 — intervention group
Group type: COMPARATOR
Intervention: Water, milk, broth, tea, and chocolate drinks instead of coffee
Number of subjects: 64
Study 9394654 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. contrast-enhanced spiral-CT
Number of subjects: 35
Study 9394654 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. contrast-enhanced spiral-CT + spiral-CTAP
Number of subjects: 35
Study 9394654 — intervention group
Group type: EXPERIMENTAL
Intervention: plain MR
Number of subjects: 35
Study 9394654 — intervention group
Group type: EXPERIMENTAL
Intervention: plain MR + SPIO-enhanced MR
Number of subjects: 35
Study 9394654 — intervention group
Group type: EXPERIMENTAL
Intervention: spiral-CTAP
Number of subjects: 35
Study 9394654 — intervention group
Group type: COMPARATOR
Intervention: SPIO-enhanced MR
Number of subjects: 35
Study 8282251 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg/day
Number of subjects: 399
Study 8282251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 3321397 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid treatment with additional ranitidine
Number of subjects: 56
Study 3321397 — intervention group
Group type: COMPARATOR
Intervention: Low-dose antacid treatment without ranitidine
Number of subjects: 56
Study 30591198 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diltiazem applied three times a day
Number of subjects: 52
Study 30591198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 28931618 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (warfarin)
Number of subjects: 3623
Study 28931618 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk scores (HEMORR2HAGES, Shireman, HAS-BLED, ATRIA, ORBIT)
Number of subjects: 3623
Study 26598477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 301
Study 26598477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 22554354 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg day(‐1) for 4 days)
Number of subjects: 17
Study 22554354 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg day(‐1) for 6 days)
Number of subjects: 17
Study 22554354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 22567069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-based stress management tool used three times daily
Number of subjects: 40
Study 22567069 — intervention group
Group type: COMPARATOR
Intervention: Control group with no specific intervention
Number of subjects: 40
Study 22567069 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-based stress management tool during the 28-day extension period
Number of subjects: 40
Study 22567069 — intervention group
Group type: COMPARATOR
Intervention: Control group during the 28-day extension period
Number of subjects: 40
Study 18635021 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17075849 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (up to 15 sessions in a 3-month period)
Number of subjects: 357
Study 17075849 — intervention group
Group type: COMPARATOR
Intervention: Control (no acupuncture)
Number of subjects: 357
Study 17075849 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (nonrandomized group)
Number of subjects: 357
Study 12930581 — intervention group
Group type: EXPERIMENTAL
Intervention: MIFT (tubal‐replaced microinjected oocytes)
Number of subjects: 63
Study 12930581 — intervention group
Group type: COMPARATOR
Intervention: ICSI-embryo transfer (conventional day 2 embryo transfer)
Number of subjects: 63
Study 10630736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg daily for 12 weeks
Number of subjects: 96
Study 10630736 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine 20 mg daily for 12 weeks
Number of subjects: 96
Study 10630736 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 96
Study 10630736 — intervention group
Group type: COMPARATOR
Intervention: Nitrendipine
Number of subjects: 96
Study 8852531 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 62
Study 8852531 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 1531551 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program including information on back care, physical fitness, nutrition, stress, and relaxation.
Number of subjects: 0
Study 1531551 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified what intervention was received).
Number of subjects: 0
Study 6391236 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 50 g of glucose added to porcine insulin (0.4 Ul.g-1)
Number of subjects: 48
Study 6391236 — intervention group
Group type: COMPARATOR
Intervention: Glucose infusion without insulin
Number of subjects: 48
Study 30854449 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparametric imaging biomarker for tumor hyperperfusion and hypercellularity (DCE-MRI and high b-value DW-MRI)
Number of subjects: 12
Study 29351748 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication (acetaminophen)
Number of subjects: 119
Study 29351748 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 119
Study 29351748 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 119
Study 26256457 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia initiative program implemented in 36 hospitals after identifying drawbacks in stage 1.
Number of subjects: 599214
Study 24557758 — intervention group
Group type: EXPERIMENTAL
Intervention: Mydriasert (ophthalmic insert containing tropicamide and phenylephrine)
Number of subjects: 77